Allen Barbieri Biography and Net Worth

Vice Chairman of Biomerica

Mr. Allen Barbieri served as an independent outside Director of the Company from October 1999 to August 2020, and from August 2020 to present has served as an Executive Director and as Vice Chairman. Mr. Barbieri also serves as Corporate Secretary of the Company. From March 2015 to April 2022, Mr. Barbieri also served as a member of the board of directors of CareTrust REIT, Inc. (NYSE:CTRE), a publicly traded real estate investment trust, where he served as Chairman of the Corporate Governance and Nominating Committee and also served on the Audit and Compensation Committees. From January 2010 to March 2018 Mr. Barbieri served as the Chief Executive Officer of Biosynthetic Technologies, a privately held, renewable specialty chemicals company, with BP and Monsanto as primary owners. Prior to that, from April 2004 to September 2009, Mr. Barbieri served as the Chief Executive Officer of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico. From 1998 to 1999, he served as President and Chief Financial Officer of BUY.COM, a major internet retailer and from 1994 to 1999 Mr. Barbieri was President and Chief Executive Officer of Pacific National Bank. Mr. Barbieri hold an MBA degree from MIT University.

What is Allen Barbieri's net worth?: The estimated net worth of Allen Barbieri is at least $140.47 thousand as of August 26th, 2026. Mr. Barbieri owns 73,542 shares of Biomerica stock worth more than $140,465 as of October 8th. This net worth evaluation does not reflect any other investments that Mr. Barbieri may own. Learn More about Allen Barbieri's net worth.
How do I contact Allen Barbieri?: The corporate mailing address for Mr. Barbieri and other Biomerica executives is 17571 Von Karman Avenue, Irvine CA, 92614. Biomerica can also be reached via phone at (949) 379-2875 and via email at [email protected]. Learn More on Allen Barbieri's contact information.
Has Allen Barbieri been buying or selling shares of Biomerica?: Allen Barbieri has not been actively trading shares of Biomerica within the last three months. Most recently, on Wednesday, August 26th, Allen Barbieri bought 20,000 shares of Biomerica stock. The stock was acquired at an average cost of $1.60 per share, with a total value of $32,000.00. Following the completion of the transaction, the insider now directly owns 73,542 shares of the company's stock, valued at $117,667.20. Learn More on Allen Barbieri's trading history.
Are insiders buying or selling shares of Biomerica?: During the last twelve months, Biomerica insiders bought shares 4 times. They purchased a total of 92,500 shares worth more than $148,000.00. The most recent insider tranaction occured on August, 26th when Director David Moatazedi bought 10,000 shares worth more than $16,000.00. Insiders at Biomerica own 18.0% of the company. Learn More about insider trades at Biomerica.
Information on this page was last updated on 8/26/2026.

Allen Barbieri Insider Trading History at Biomerica

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/26/2026	Buy	20,000	$1.60	$32,000.00	73,542
1/27/2023	Buy	192	$23.52	$4,515.84	12,665
8/9/2016	Buy	375	$20.32	$7,620.00	12,486

Allen Barbieri Buying and Selling Activity at Biomerica

Biomerica Company Overview

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Today's Range

Now: $1.89

$1.88

$1.91

50 Day Range

MA: $2.01

$1.49

$2.78

2 Week Range

Now: $1.89

$1.45

$3.21

Volume

1,736 shs

Average Volume

36,817 shs

Market Capitalization

$5.84 million

P/E Ratio

N/A

Dividend Yield